Australia sends mixed message with China visit and war drills
Talisman Sabre is the biennial exercise dating back to the mid-2000s. This year, it involves almost 40,000 troops and 19 nations. And a not-too-subtle hint: they are united in preparing against an aggressive and expansionist China.
Talk about Canberra sending mixed messages to Beijing!
The press releases put out earlier by the defence departments of Australia and the US were positively breathless.
'Talisman Sabre 2025 is the largest and most sophisticated warfighting exercise ever conducted in Australia,' the Australian version read.
'Over the next three weeks, more than 35,000 military personnel from Australia and partnering nations will deploy across Queensland, Northern Territory, Western Australia, New South Wales and Christmas Island. For the first time, activities will also be conducted outside of Australia in Papua New Guinea.'
Poor New Guinea! But when your two overlords say so, you don't have much of a choice. Likewise with Fiji and Tonga, two other 'allies' called to duty to boost the numbers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
9 minutes ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
South China Morning Post
an hour ago
- South China Morning Post
InvestHK at 25: powering growth for global firms in Hong Kong and beyond
When InvestHK was established in July 2000, its mission was clear: attract overseas and mainland Chinese companies to establish or expand in Hong Kong, reinforcing its position as 'Asia's world city'. Twenty-five years on, that mission remains unchanged, but the tools and the scale of support have evolved significantly. Advertisement This year, both InvestHK and Hong Kong Exchanges and Clearing (HKEX) marked their silver jubilees with notable results. In 2024, InvestHK assisted a record 539 mainland Chinese and overseas companies in setting up operations in Hong Kong. Since its establishment in 2000, 145 of InvestHK's clients have listed on HKEX. Between January 2023 and June 2025, InvestHK helped more than 1,300 companies set up or expand in Hong Kong, bringing in over HK$160 billion (US$20 billion) in foreign direct investment. These companies created more than 19,000 jobs in their first year of operation, exceeding the government's 2022 Policy Address targets ahead of schedule. Hong Kong's initial public offering (IPO) market has maintained steady momentum in 2025, with HKEX recording more than 50 listings between January and mid-July, a year-on-year increase of 30 per cent. The exchange ranked first globally in IPO fundraising during the period, with more than 200 companies actively preparing for a public offering in the second half of the year. Support from InvestHK for overseas and mainland Chinese companies and institutions includes planning, setting up and expanding their operations in Hong Kong. The agency provides strategic advice on market entry, practical guidance during the establishment and launch phases, and continued support as businesses grow and scale across international markets via Hong Kong. When an IPO is on the horizon, InvestHK offers pre-listing workshops covering disclosure, environmental, social and governance (ESG), and investor-relations requirements, enabling founders to scale up without needing to shift jurisdictions, a stability that is increasingly valued in an era of geopolitical uncertainty. Advertisement Beyond projects: building ecosystems
South China Morning Post
an hour ago
- South China Morning Post
Hong Kong 47: third batch of opposition activists freed after 4 years in prison
Three more activists among the 47 Hong Kong opposition figures charged in the city's largest national security case for conspiracy to commit subversion have been released from prison. Former union leader Carol Ng Man-yee, and activists Nathan Lau Chak-fung and Frankie Fung Tak-chun were the third batch of defendants in the landmark case to complete their four-year-and-five-month sentences. The trio, who pleaded guilty, were separately sent to their residences in vans from the Lo Wu Correctional Institution and Stanley Prison on Monday morning. Asked about his feelings, Lau put on a smile and shook his head while walking towards his block. Nathan Lau was freed from prison after completing his sentence under the national security law. Photo: Handout Lau, 28, was the president of the student union at Hong Kong Shue Yan University and a standing committee member of the Hong Kong Federation of Students. Ng, now 54, was a flight attendant at British Airways. She founded the BA Hong Kong International Cabin Crew Association and had mounted several legal challenges against the employer over wages, anti-union practices, age and sex discrimination.
